首页> 外文会议>European Congress of Neurosurgery >Transsphenoidal Surgery for Cushing's Disease: An Institutional Perspective of Follow-up and Monitoring of 59 Patients
【24h】

Transsphenoidal Surgery for Cushing's Disease: An Institutional Perspective of Follow-up and Monitoring of 59 Patients

机译:用于缓冲疾病的经胸腔外科:59名患者的后续和监测的制度观点

获取原文

摘要

Transsphenoidal surgery is the first choice treatment modality for ACTH pituitary adenomas. We retrospectively reviewed the 59 Cushing's disease patients (pts) diagnosed and operated at our institution between 1981 and 2003. Fifty eight pts were transsphenoidally operated, 8 underwent reoperations, because of surgical failure (6 pts) or recurren-ce (2 pts). The mean postoperative follow-up period was 10.2 + 4.8 years. Remission was achieved in 79.6 % of all (47 pts) after one operation and for 60% of the patients who underwent a second operation (5 pts). The long term recurrence rate was 3% (2 pts). After unsuccessful surgery 4 pts were submitted to conventional pituitary radiotherapy: 3 were cured and 1 developed radiation induced optic neuropathy. One pt was treated with a PPARg agonist rosiglitazone. Our series demonstrates the efficacy of transsphenoidal surgery for Cushing's disease.
机译:Transphenoidal手术是Acth垂体腺瘤的首选治疗方式。我们回顾性地审查了1981年至2003年间在我们的机构诊断和运营的59名缓冲疾病患者(PTS)。五十八分钟被转诊,由于手术失败(6分)或重复性 - CE(2分)。平均术后随访时间为10.2 + 4.8岁。在一次操作后的79.6%的79.6%的79.6%和60%接受第二次操作的患者(5分)的患者中取得了缓解。长期复发率为3%(2分)。在不成功的手术后,4分钟被提交给常规的垂体放射治疗:3被固化,1个发达的辐射诱导光学神经病变。用PPARG激动剂Rosiglitazone治疗一个Pt。我们的系列展示了双耳体外手术对缓冲疾病的疗效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号